Nanexa publishes interim report for January-March 2024

3 May, 2024
- Regulatory

NEX-22 clinical trial preparations ongoing and Novo Nordisk collaboration progressing well

Significant events during the first quarter 2024

  • No significant event during the quarter.

Significant events after the end of the period

  • Nanexa announced that in the ongoing review process of the clinical trial application for the phase I study with NEX-22, additional supplements have been requested from the German Medicines Agency, which in the new European regulatory process takes more time than expected. The company estimates that it can obtain approval and start the study towards the end of the second quarter of 2024.

Financial overview

1 January – 31 March 2024

  • Turnover amounted to: TSEK 7,754 (8,173)
  • Operating profit (EBIT) amounted to: TSEK -3,363 (-8,703)
  • Profit after tax amounted to: TSEK -2,823 (-8,603)
  • Earnings per share amounted to: SEK -0.02 (-0.14)
  • Cash flow for the period amounted to: TSEK -17,328 (-20,682)
  • Cash and cash equivalents at end of period: TSEK 47,839 (60,500)

Figures in brackets refer to the corresponding period in the previous year.

The entire report is available on the company’s website:

Report commentary, May 3 at 12:00 CET

A live commentary with CEO David Westberg will take place on May 3 at 12:00 noon via Infront Direkt Studios and viewers will have the opportunity to ask questions via chat. The presentation will be held in Swedish.

The report commentary will be available via this link.

The report commentary will also be published on Nanexa's website afterwards.